Authors
Latest:
Tremelimumab Combo Improves OS Vs Sorafenib in Unresectable Liver CancerTreatment with the tremelimumab-based combination also yielded no new serious treatment-related adverse effects in the HIMALAYA study.
Latest:
Cell-Free DNA Assay Achieves High Negative Predicative Value in Lung CancerAn 80% sensitivity for lung cancer was observed with the liquid biopsy, with high sensitivity observed for early-stage disease, as well.
Latest:
Emerging Front-Line Maintenance Therapies for Advanced Ovarian CancerDr. Rebecca Previs shares data on some exiting emerging therapies in the front line setting for patients with advanced ovarian cancer.
Latest:
Optimal Sequencing Between CAR T and Bispecifics in Multiple MyelomaThe use of CAR T-cell therapy and other sequencing options were discussed for patients with multiple myeloma.
Latest:
Future Perspectives in the Treatment of Chronic Lymphocytic LeukemiaConcluding their discussion, Drs Advani, Parrondo, and Chanan-Khan conclude that second-generation BTK inhibitors are the preferred first-line treatment in patients with chronic lymphocytic leukemia due to better efficacy and lower cardiovascular risk, with emerging therapies promising even better outcomes.
Latest:
Expert Discusses Screening Advocacy, AI, and Developments in Breast CancerEarly screening for breast cancer may help match patients with appropriate systemic therapies depending on the extent of their tumors, according to Rakhshanda Rahman, MD, FRCS, FACS.
Latest:
Metastatic Basal Cell Carcinoma Arising From a Primary Cutaneous CarcinosarcomaThis study presents a case of a man, aged 56 years, found to have a 26-mm exophytic lesion on the vertex scalp identified to contain a distinct population of basal cell carcinoma as well as another population of spindled cells representing a poorly differentiated sarcomatous component.
Latest:
Extreme Case of Surgical Port Metastasis in Ovarian CancerWe present the case of a 51-year-old woman with metastatic International FIGO stage IIIC ovarian cancer who had delayed her therapy after initial laparoscopy due to COVID-19 infection and presented with an extreme case of surgical port metastasis.
Latest:
‘Absolutely Important’ to Develop Better Ways to Predict Kidney Cancer Recurrence, Says ExpertFuture research must address ways to improve the prediction of kidney cancer recurrence to better inform patients, says an expert from the Royal Free London NHS Foundation Trust.
Latest:
Shorter Time to Treatment Is Associated With Improved Survival in Rural Patients With Breast Cancer Despite Other Adverse Socioeconomic FactorsMinh-Tri Nguyen, MD, and colleagues investigate the association between time to treatment, socioeconomic status, and clinical outcomes among rural and urban patients with breast cancer.
Latest:
Oligoprogression After Immunotherapy and Targeted Therapy in Metastatic MelanomaThis clinical quandary discusses oligoprogressive disease in metastatic melanoma and how treatment with immunotherapy and targeted therapy affect the disease.
Latest:
Real-World Assessment of Patient Care and Practice Efficiency With the Introduction of Subcutaneous RituximabRituximab-subcutaneously is associated with significantly reduced chair time vs rituximab-intravenously in a US oncology setting. Widespread adoption would be expected to improve practice efficiency and patient access to care, and to reduce health care resource burden.
Latest:
Key Presentations at ASCO 2021 Review Primary Prevention of Prostate Cancer in African American MenCancerNetwork® sat down with Edmund Qiao at the 2021 American Society of Clinical Oncology Annual Meeting to talk about prostate-specific antigen screening and prostate cancer prevention in African American men.
Latest:
Cross Q&A: Isa + KD in Relapsed/Refractory MM and Biochemical vs Clinical ProgressionIn the final cross Q&A session from the multiple myeloma module, panelists discuss implications of IKEMA and consider the importance of biochemical versus clinical progression.
Latest:
Extending the Benefits of Avelumab Maintenance in Urothelial CarcinomaOngoing research may clarify the potential benefit of avelumab when administered in combination with other agents in advanced urothelial carcinoma.
Latest:
Current Treatment of Peripheral T-cell LymphomaThis review article written by Robert Stuver, MD, et al, reviews current and available treatments for peripheral T-cell lymphoma.
Latest:
Pancreatic Neuroendocrine Tumor With Humoral Hypercalcemia and High Tumor PD-L1 ScoreAbstract: Pancreatic neuroendocrine tumors (NETs) are a heterogeneous group of neoplasms. They can be functioning tumors with secretion of a variety of peptide hormones, or nonfunctioning tumors with metastases to the liver at the time of diagnosis. Well-differentiated tumors tend to be slow-growing and characterized by low tumor mutational burden (TMB) and lower propensity to express PD-L1. Hypercalcemia due to malignancy can occur in about 20% to 30% of patients with cancer. The secretion of parathyroid hormone–related protein (PTH-rP) is among the causes of malignant hypercalcemia and has seldom been associated with hypercalcemia of NETs. Although the therapeutic landscape for neuroendocrine neoplasms has evolved substantially over the past decade, the role of immunotherapy has not yet been completely explored in this group of patients. We present a rare case of a metastatic pancreatic NET with high TMB, high PD-L1 tumor proportion score, and high PTH-rP–related hypercalcemia.
